(R)-(+)-4-异丙基-5,5-二甲基-2-恶唑烷酮

反应条件: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

实验步骤: By reaction and treatment in the same manner as in Example 1 and using (4-bromo-2-methanesulfonylphenyl)[4-(3,5-dimethylpyridin-2-yl)piperazin-1-yl]methanone (890 mg) described in Preparation Example 61 and (R)-(+)-4-isopropyl-5,5-dimethyloxazolidin-2-one (409 mg), the title compound (51 mg) was obtained. By reaction and treatment in the same manner as in Example 1

反应条件: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

实验步骤: By reaction and treatment in the same manner as in Example 1 and using (4-bromo-2-methylphenyl)[4-(3,5-dimethylpyridin-2-yl)piperazin-1-yl]methanone (867 mg) described in Preparation Example 67 and (R)-(+)-4-isopropyl-5,5-dimethyloxazolidin-2-one (409 mg), the title compound (35 mg) was obtained. By reaction and treatment in the same manner as in Example 1

反应条件: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

实验步骤: By reaction and treatment in the same manner as in Example 1 and using (4-bromo-2-methanesulfonylphenyl)[4-(2,4-dimethylphenyl)piperazin-1-yl]methanone (722 mg) described in Preparation Example 9 and (R)-(+)-4-isopropyl-5,5-dimethyloxazolidin-2-one (250 mg), the title compound (359 mg) was obtained. By reaction and treatment in the same manner as in Example 1